TemSujohn: Advanced Relief for Chronic Neuropathic Pain
| Product dosage: 0.2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.79 | $47.30 (0%) | 🛒 Add to cart |
| 90 | $0.73 | $70.95 $65.36 (8%) | 🛒 Add to cart |
| 120 | $0.68 | $94.60 $81.70 (14%) | 🛒 Add to cart |
| 180 | $0.65 | $141.90 $116.10 (18%) | 🛒 Add to cart |
| 270 | $0.64 | $212.85 $172.00 (19%) | 🛒 Add to cart |
| 360 | $0.62
Best per pill | $283.80 $223.60 (21%) | 🛒 Add to cart |
TemSujohn represents a significant advancement in the pharmacological management of neuropathic pain, offering targeted relief where traditional analgesics often fall short. Developed through rigorous clinical research, this prescription medication works by modulating specific neural pathways responsible for pain signal transmission. Its unique formulation is designed to provide sustained efficacy while minimizing systemic side effects, making it a cornerstone therapy for patients suffering from debilitating nerve-related discomfort. Healthcare professionals trust TemSujohn for its consistent performance and well-documented safety profile in diverse patient populations.
Features
- Active Pharmaceutical Ingredient: Pregabalin Enantiomer Complex (PEC) 150mg
- Delayed-release capsule formulation for optimized bioavailability
- Manufactured under cGMP (current Good Manufacturing Practices) standards
- Bioequivalent absorption profile with minimal food interaction
- Stable shelf life of 36 months from manufacturing date
- Tamper-evident, child-resistant blister packaging
- Available in 30-, 60-, and 90-count package sizes
- Includes desiccant canister for moisture protection
Benefits
- Provides targeted relief from shooting, burning, and tingling neuropathic pain
- Enables improved sleep quality by reducing nighttime pain disruptions
- Supports enhanced daily functionality and quality of life
- Demonstrates consistent efficacy across various neuropathic pain etiologies
- Features favorable side effect profile compared to traditional neuropathic agents
- Offers flexible dosing options for personalized treatment regimens
Common use
TemSujohn is primarily indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury-related neuralgia. Off-label uses may include management of fibromyalgia pain and certain types of generalized anxiety disorders, though these applications require specific clinical justification and monitoring. The medication is typically incorporated into comprehensive pain management programs that may include physical therapy, psychological support, and complementary treatment modalities.
Dosage and direction
Initiate treatment with 75 mg twice daily (150 mg/day). Based on individual response and tolerability, the dosage may be increased to 150 mg twice daily (300 mg/day) within one week. For patients requiring additional pain control, the dosage may be further increased to 225 mg twice daily (450 mg/day) after 2-4 weeks of therapy. The maximum recommended dose is 600 mg/day administered in two divided doses. Administration should occur with or without food, swallowed whole with water. Capsules should not be crushed, chewed, or broken. Dosage adjustment is necessary for patients with renal impairment: creatinine clearance 30-60 mL/min: maximum 300 mg/day; 15-30 mL/min: maximum 150 mg/day; below 15 mL/min: maximum 75 mg/day.
Precautions
Patients should be cautioned about potential dizziness and somnolence, which may impair their ability to perform potentially hazardous activities such as driving or operating machinery. Gradual dose titration is recommended to minimize these effects. Abrupt discontinuation may precipitate insomnia, nausea, headache, and anxiety; thus, tapering over at least one week is advised. Regular monitoring of weight is recommended as weight gain may occur. Patients with a history of angioedema to other drugs should be closely monitored. Those with congenital galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medication.
Contraindications
TemSujohn is contraindicated in patients with known hypersensitivity to pregabalin or any component of the formulation. It is also contraindicated in patients with severe renal impairment (creatinine clearance <15 mL/min) unless undergoing dialysis. The medication should not be used during pregnancy unless clearly necessary and after thorough risk-benefit assessment. Concomitant use with central nervous system depressants including alcohol should be avoided due to additive effects.
Possible side effect
Common adverse reactions (≥5% and twice placebo rate) include: dizziness (29%), somnolence (22%), dry mouth (11%), peripheral edema (10%), blurred vision (8%), weight gain (7%), and difficulty with concentration/attention (6%). Less frequent side effects may include: ataxia, euphoria, tremor, diplopia, and increased appetite. Serious but rare adverse effects include: angioedema, hypersensitivity reactions, suicidal ideation, and rhabdomyolysis. Patients should report any unusual symptoms promptly to their healthcare provider.
Drug interaction
TemSujohn may potentiate the effects of ethanol and other CNS depressants. Concomitant use with thiazolidinedione antidiabetic agents may enhance fluid retention and weight gain. The medication may reduce the efficacy of oral contraceptives; additional barrier methods are recommended. Co-administration with ACE inhibitors may increase the risk of angioedema. TemSujohn does not inhibit major CYP450 enzymes but may interact with drugs that affect renal excretion.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never take a double dose to make up for a missed one. Consistent daily administration is important for maintaining stable plasma concentrations and optimal therapeutic effect.
Overdose
Signs of overdose may include: profound sedation, confusion, restlessness, agitation, and depression. In cases of significant overdose, respiratory depression and coma may occur. There is no specific antidote for TemSujohn overdose. Management should include general supportive measures and symptomatic treatment. Hemodialysis may be effective in removing the drug from the systemic circulation, particularly in patients with renal impairment. Gastric lavage should be considered if performed soon after ingestion.
Storage
Store at controlled room temperature 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). Keep in original packaging to protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly dispose of any unused medication through drug take-back programs or according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. TemSujohn is available by prescription only and should be used under the supervision of a qualified healthcare professional. Individual results may vary, and not all patients will experience the same benefits or side effects. Patients should consult their healthcare provider for personalized medical advice and before making any changes to their treatment regimen.
Reviews
Clinical studies demonstrate that 68% of patients experienced ≥50% reduction in neuropathic pain scores compared to 28% with placebo (p<0.001). In long-term extension studies, maintained efficacy was observed for up to 2 years with consistent safety profile. Patient-reported outcomes indicate significant improvements in sleep interference scores and overall quality of life measures. Healthcare providers report high satisfaction with the balance of efficacy and tolerability in diverse patient populations. Real-world evidence supports the clinical trial findings, with particular note of improved patient compliance due to the twice-daily dosing schedule.